Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Hospital Anxiety and Depression Scale (HADS)
研究概览
简要总结
The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs
详细描述
The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age >18 years
- •diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria
- •being able to compile questionnaire
- •current treatment with biological disease-modifying antirheumatic drug
排除标准
- •Current treatment for anxiety or depressive disorder
结局指标
主要结局
Hospital Anxiety and Depression Scale (HADS)
时间窗: 1 day of enrollement
Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.
次要结局
未报告次要终点